Science & Technology
In vivo targeted delivery of nucleic acids to hematopoietic stem cells for treating primary immunodeficiencies
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43AI188970-01A1
Award Ceiling
$300K
Award Floor
$300K
Close Date
Jul 31, 2027
503 days leftTotal Funding
$300K
Expected Awards
1
Posted Date
Aug 19, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R43AI188970-01A1
Description
SBIR Phase Phase I award: "In vivo targeted delivery of nucleic acids to hematopoietic stem cells for treating primary immunodeficiencies" awarded to Optimeos Life Sciences, Inc. in PRINCETON, New Jersey. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $300,000. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.